关于控股股东、持股5%以上股东部分股份质押及解除质押的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 一、股东股份质押基本情况 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：301331 证券简称：恩威医药 公告编号：2025-055 恩威医药股份有限公司 ■ 上述股东及其一致行动人累计质押股份数量占其所持公司股份数量比例超过50%，现就相关情况说明如 下： 1、本次股份质押不用于满足上市公司生产经营需求； 2、恩威集团及其一致行动人未来半年内到期的累计质押股份数量为14,140,836股，占其所持公司股份的 19.89%，占公司总股本的13.74%，对应融资余额为16,000万元；未来一年内到期的累计质押股份数量为 54,420,836 股，占其所持公司股份的76.54%，占公司总股本的52.89%，对应融资余额为55,600万元。公 司及其一致行动人具备相应的资金偿还能力，还款资金来源为自有及自筹资金。 3、截至本公告披露日，上述股东及其一致行动人不存在非经营性资金占用、违规担保等侵害上市公司 利益的情形； 4、上述股东及其一致行动人股 ...

Core Viewpoint - Hongyuan Pharmaceutical's products, Pudilan Anti-inflammatory Tablets and Qingre Jiedu Oral Liquid, are effective in anti-inflammatory and antiviral treatments [2] Group 1 - The company responded to investor inquiries on October 31 regarding the efficacy of its products [2] - Pudilan Anti-inflammatory Tablets and Qingre Jiedu Oral Liquid are highlighted for their anti-inflammatory and antiviral properties [2] - The company advises that medication should be taken according to medical advice or consultation with a licensed physician [2]

Group 1: Financial Performance - In 2024, the company achieved operating revenue of 812.13 million yuan, a year-on-year increase of 3.43% [7] - The net profit attributable to shareholders was 37.50 million yuan, showing a decline compared to the previous year due to non-operating factors [7] - The company aims for a revenue target of 1 billion yuan and plans to double its net profit in 2025 [5] Group 2: Sales and Profit Margins - The gross margin for online sales is approximately 60%, while offline sales have a gross margin of around 50% [2] - The company is focusing on expanding its online sales, which require higher promotional expenses [2] Group 3: Strategic Initiatives - External mergers and acquisitions are a key strategy for future growth, with the company actively monitoring potential targets [3] - The company has successfully restructured Henan Xinxin Pharmaceutical, adding 125 products to its portfolio, including 4 exclusive items [3] - Plans to launch 30 new non-pharmaceutical personal care products in 2025, targeting various consumer segments [6] Group 4: Product Development and Market Expansion - The company is prioritizing the launch of key products from Henan Xinxin Pharmaceutical, with the first batch including antiviral oral liquids and heat-clearing detoxification oral liquids [5] - The company aims to cultivate 8 to 10 products with annual sales exceeding 100 million yuan, ensuring long-term sustainable growth [6] - Continuous collaboration with hospitals and research institutions to enhance the value of core products like Jier Yin Wash [3][7]